Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OASiS-1: Phase 1/1b safety trial of OZTx-410 iPSC-derived islet cell sheet in type 1 diabetes
jRCT2053240146Phase 1Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jan 2025
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of OZTx-410 in diabetes mellitus type 1 (T1D), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Primary safety endpoint at 1 year. Started Jan 2025; status: active, not recruiting.
02
Drugs
OZTx-410
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on jRCT2053240146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2053240146.